Remimazolam vs Propofol in Laser Burn Cases
Comparison of Remimazolam Versus Propofol for Monitored Anesthetic Care in Elective Fractional Ablative CO₂ Laser
Medical University of South Carolina
136 participants
Nov 12, 2025
INTERVENTIONAL
Summary
This randomized, single-blind, crossover study compares remimazolam and propofol for monitored anesthetic care during fractional ablative CO₂ laser therapy for burn scars. The primary aim is to assess incidence of respiratory depression, defined as a need for advanced airway maneuvers (jaw thrust/chin lift, insertion of oral or nasal airway, or bag mask ventilation), and hypopnea (respiratory rate \< 8).
Eligibility
Inclusion Criteria2
- Age ≥ 18 years
- Undergoing both outpatient Session #1 and Session #2 of fractional ablative CO2 laser therapy
Exclusion Criteria5
- History of previous fractional ablative laser therapy for burn scar
- Procedure expected to last longer than 30 minutes
- Allergy such as dextran 40 or contraindication to either of the study drugs
- Pregnant and/or breastfeeding
- Subjects who are unable to or choose not to give informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Remimazolam
Propofol
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07213544